PRESS RELEASE published on 01/05/2024 at 03:00, 1 year 11 months ago Quantas Labs Secures $550K in Seed Funding to Propel AI-Driven Erosion Impact Forecasting Technology Quantas Labs, the pioneering force behind the world's first commercial AI for erosion impact prediction, has successfully closed a $550K seed funding round. Led by founder Alex Pourquery, the London-based company aims to deliver cutting-edge erosion forecasting solutions vital for sustainable land management. Their proprietary technology combines advanced hybrid AI framework, real-time data integration, advanced soil type classification, and robust data handling to revolutionize erosion impact prediction. The seed funding will significantly boost development and go-to-market strategies, accelerating their path to becoming a leader in geotechnical analysis. Quantas Labs AI Erosion Impact Prediction Seed Funding Round Geospatial Datasets Sustainable Land Management
Published on 12/05/2025 at 02:35, 4 hours 48 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 23 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 18 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 23 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 23 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 53 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 32 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 58 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 8 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 8 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 23 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 23 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 38 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 38 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL